<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33003404</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2198</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells9102198</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by the progressive death of both upper and lower motor neurons. The disease presents a poor prognosis, and patients usually die 2-5 years after the onset of symptoms. The hallmark of this disease is the presence of phosphorylated and ubiquitinated aggregates containing trans-active response DNA-binding protein-43 (TDP-43) in the cytoplasm of motor neurons. TDP-43 pathology has been associated with multiple pathways in ALS, such as metabolic dysfunction found in patients and in in vivo models. Recently, it has been described as a "prion-like" protein, as studies have shown its propagation in cell culture from ALS brain extract or overexpressed TDP-43 in co-culture and conditioned medium, resulting in cytotoxicity. However, the cellular alterations that are associated with this cytotoxicity require further investigation. Here, we investigated the effects of conditioned medium from HEK293T (Human Embryonic Kidney 293T) cells overexpressing TDP-43 on cellular morphology, proliferation, death, and metabolism. Although we did not find evidence of TDP-43 propagation, we observed a toxicity of TDP-43-conditioned medium and altered metabolism. These results, therefore, suggest (1) that cells overexpressing TDP-43 produce an extracellular environment that can perturb other cells and (2) that TDP-43 propagation alone may not be the only potentially cytotoxic cell-to-cell mechanism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>INSERM, UMR 1253, iBrain, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanznaster</LastName><ForeName>D&#xe9;bora</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5911-3120</Identifier><AffiliationInfo><Affiliation>INSERM, UMR 1253, iBrain, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeais</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CNRS ERL7001, EA 7501 GICC, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;rault</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-7419-1124</Identifier><AffiliationInfo><Affiliation>CNRS ERL7001, EA 7501 GICC, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7960-8139</Identifier><AffiliationInfo><Affiliation>INSERM, UMR 1253, iBrain, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>INSERM, UMR 1253, iBrain, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, UMR 1253, iBrain, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>INSERM, UMR 1253, iBrain, Universit&#xe9; de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword><Keyword MajorTopicYN="N">prion-like</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33003404</ArticleId><ArticleId IdType="pmc">PMC7601466</ArticleId><ArticleId IdType="doi">10.3390/cells9102198</ArticleId><ArticleId IdType="pii">cells9102198</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gil-Bea F.J., Aldanondo G., Fernandez H.L., Vallejo-Illarramendi A., De Munain A.L. Insights into the mechanisms of copper dyshomeostasis in amyotrophic lateral sclerosis. Expert Rev. Mol. Med. 2017;19:17085. doi: 10.1017/erm.2017.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/erm.2017.9</ArticleId><ArticleId IdType="pubmed">28597807</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R.C., Chami A.A., De Assis D.R., Vourc&#x2019;H P., Andres C.R., Corcia P., Lanznaster D., Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>King O.D., Gitler A.D., Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80. doi: 10.1016/j.brainres.2012.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.01.016</ArticleId><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarev V.F., Benken K.A., Semenyuk P.I., Sarantseva S.V., Bolshakova O.I., Mikhaylova E.R., Muronetz V.I., Guzhova I.V., Margulis B.A. GAPDH binders as potential drugs for the therapy of polyglutamine diseases: Design of a new screening assay. FEBS Lett. 2015;589:581&#x2013;587. doi: 10.1016/j.febslet.2015.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.01.018</ArticleId><ArticleId IdType="pubmed">25625921</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury J.J., McAlary L. Strategies to promote the maturation of ALS-associated SOD1 mutants: Small molecules return to the fold. Neural Regen. Res. 2019;14:1511&#x2013;1512. doi: 10.4103/1673-5374.255962.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.255962</ArticleId><ArticleId IdType="pmc">PMC6557088</ArticleId><ArticleId IdType="pubmed">31089043</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgucheva I., Sharov V.S., Surguchov A. gamma-Synuclein: Seeding of alpha-synuclein aggregation and transmission between cells. Biochemistry. 2012;51:4743&#x2013;4754. doi: 10.1021/bi300478w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi300478w</ArticleId><ArticleId IdType="pubmed">22620680</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F., Maniecka Z., P&#xe9;rez-Berlanga M., Hruska-Plochan M., Gilhespy L., Hock E.-M., Wagner U., Afroz T., Boersema P.J., Barmettler G., et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci. 2018;22:65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Masuda-Suzukake M., Arai T., Hasegawa Y., Akatsu H., Obi T., Yoshida M., Murayama S., Mann D.M., Akiyama H., et al. Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains. Cell Rep. 2013;4:124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P., Newcombe J., Troakes C., Simone R., Chen Y.-R., Patani R., Sidle K. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol. Dis. 2016;96:236&#x2013;247. doi: 10.1016/j.nbd.2016.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.08.007</ArticleId><ArticleId IdType="pmc">PMC5113659</ArticleId><ArticleId IdType="pubmed">27590623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeineddine R., Whiten D.R., Farrawell N.E., McAlary L., Hanspal M.A., Kumita J.R., Wilson M.R., Yerbury J.J. Flow cytometric measurement of the cellular propagation of TDP-43 aggregation. Prion. 2017;11:195&#x2013;204. doi: 10.1080/19336896.2017.1314426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336896.2017.1314426</ArticleId><ArticleId IdType="pmc">PMC5480386</ArticleId><ArticleId IdType="pubmed">28486039</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiler M.S., Strobel B., Freischmidt A., Helferich A.M., Kappel J., Brewer B.M., Li D., Thal D.R., Walther P., Ludolph A.C., et al. TDP-43 is intercellularly transmitted across axon terminals. J. Cell Boil. 2015;211:897&#x2013;911. doi: 10.1083/jcb.201504057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201504057</ArticleId><ArticleId IdType="pmc">PMC4657165</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Lanznaster D., Veyrat-Durebex C., Hergesheimer R., Vourch P., Maillot F., Andres C.R., Pradat P.-F., Corcia P. Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis. Expert Rev. Neurother. 2020:1&#x2013;13. doi: 10.1080/14737175.2020.1788389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1788389</ArticleId><ArticleId IdType="pubmed">32583696</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., O&#x2019;Conner A.G., Barrows J.M., Shreiner D.D., Birchak G.J., Zarnescu D.C. Medium-Chain Fatty Acids, Beta-Hydroxybutyric Acid and Genetic Modulation of the Carnitine Shuttle Are Protective in a Drosophila Model of ALS Based on TDP-43. Front. Mol. Neurosci. 2018;11:182. doi: 10.3389/fnmol.2018.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00182</ArticleId><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bourgeais J., Bruno C., Hergesheimer R.C., Thepault R.-A., Vourc&#x2019;H P., Corcia P., Andres C.R., Herault O., Blasco H., et al. TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis. Cells. 2019;9:68. doi: 10.3390/cells9010068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010068</ArticleId><ArticleId IdType="pmc">PMC7016571</ArticleId><ArticleId IdType="pubmed">31888078</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Cleveland D.W. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 2011;21:904&#x2013;919. doi: 10.1016/j.conb.2011.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2011.05.029</ArticleId><ArticleId IdType="pmc">PMC3228892</ArticleId><ArticleId IdType="pubmed">21813273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E., Grad L.I., Cashman N.R. TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion. Sci. Rep. 2016;6:22155. doi: 10.1038/srep22155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22155</ArticleId><ArticleId IdType="pmc">PMC4772009</ArticleId><ArticleId IdType="pubmed">26926802</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F., Baranek T., Vourc&#x2019;H P., Nadal-Desbarats L., Goossens J.-F., Marouillat S., Dessein A.-F., Descat A., Hounoum B.M., Bruno C., et al. Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism. Neurotherapeutics. 2016;13:905&#x2013;917. doi: 10.1007/s13311-016-0461-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0461-3</ArticleId><ArticleId IdType="pmc">PMC5081117</ArticleId><ArticleId IdType="pubmed">27444617</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen M.H., Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2010;20:167&#x2013;174. doi: 10.3233/JAD-2010-1404.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1404</ArticleId><ArticleId IdType="pubmed">20182054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hounoum B.M., Blasco H., Coque E., Vourc&#x2019;H P., Emond P., Corcia P., Andres C.R., Raoul C., Mavel S. The Metabolic Disturbances of Motoneurons Exposed to Glutamate. Mol. Neurobiol. 2018;55:7669&#x2013;7676. doi: 10.1007/s12035-018-0945-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0945-8</ArticleId><ArticleId IdType="pubmed">29435916</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J., Wishart D.S. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. Curr. Protoc. Bioinform. 2016;55:14.10.1&#x2013;14.10.91. doi: 10.1002/cpbi.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.11</ArticleId><ArticleId IdType="pubmed">27603023</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Eid L., Parent M., Soucy G., Bareil C., Riku Y., Kawai K., Takagi S., Yoshida M., Katsuno M., et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187&#x2013;3201. doi: 10.1093/brain/aww237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., De Aguilar J.-L.G. Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis? Curr. Genom. 2011;12:506&#x2013;515. doi: 10.2174/138920211797904043.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920211797904043</ArticleId><ArticleId IdType="pmc">PMC3219845</ArticleId><ArticleId IdType="pubmed">22547957</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena G.N., Rizzardini M., Cimini S., Siskos A.P., Bendotti C., Cantoni L., Keun H.C. Metabolomic Analysis Reveals Increased Aerobic Glycolysis and Amino Acid Deficit in a Cellular Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2015;53:2222&#x2013;2240. doi: 10.1007/s12035-015-9165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9165-7</ArticleId><ArticleId IdType="pmc">PMC4823370</ArticleId><ArticleId IdType="pubmed">25963727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara M., Tanaka K.-I., Kato-Negishi M. Zinc, Carnosine, and Neurodegenerative Diseases. Nutrition. 2018;10:147. doi: 10.3390/nu10020147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10020147</ArticleId><ArticleId IdType="pmc">PMC5852723</ArticleId><ArticleId IdType="pubmed">29382141</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzie J., Pan C., Prentice H., Wu J.-Y. Taurine and central nervous system disorders. Amino Acids. 2012;46:31&#x2013;46. doi: 10.1007/s00726-012-1382-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-012-1382-z</ArticleId><ArticleId IdType="pubmed">22903433</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bejan-Angoulvant T., Patin F., Andres C.R., Vourc&#x2019;H P., Corcia P., Blasco H. Plasma creatinine and amyotrophic lateral sclerosis prognosis: A systematic review and meta-analysis. Amyotroph. Lat. Scler. Front. Degener. 2019;20:199&#x2013;206. doi: 10.1080/21678421.2019.1572192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572192</ArticleId><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C., Bris C., Codron P., Bocca C., Chupin S., Corcia P., Vourc&#x2019;H P., Hergesheimer R., Cassereau J., Funalot B., et al. Metabo-lipidomics of Fibroblasts and Mitochondrial-Endoplasmic Reticulum Extracts from ALS Patients Shows Alterations in Purine, Pyrimidine, Energetic, and Phospholipid Metabolisms. Mol. Neurobiol. 2019;56:5780&#x2013;5791. doi: 10.1007/s12035-019-1484-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1484-7</ArticleId><ArticleId IdType="pubmed">30680691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Eulate G., Ruiz-Sanz J.I., Riancho J., Zufir&#xed;a M., Gere&#xf1;u G., Fern&#xe1;ndez-Torr&#xf3;n R., Poza-Aldea J.J., Ondaro J., Espinal J.B., Gonz&#xe1;lez-Chinch&#xf3;n G., et al. A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis. Amyotroph. Lat. Scler. Front. Degener. 2020;21:252&#x2013;262. doi: 10.1080/21678421.2020.1730904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1730904</ArticleId><ArticleId IdType="pubmed">32106710</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti P., Schwarcz R. Determination of &#x3b1;-aminoadipic acid in brain, peripheral tissues, and body fluids using GC/MS with negative chemical ionization. Mol. Brain Res. 2003;118:132&#x2013;139. doi: 10.1016/j.molbrainres.2003.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbrainres.2003.08.004</ArticleId><ArticleId IdType="pubmed">14559362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H.-Q., Ungerstedt U., Schwarcz R. l-&#x3b1;-Aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: A microdialysis study in freely moving rats. Eur. J. Pharmacol. 1995;281:55&#x2013;61. doi: 10.1016/0014-2999(95)00224-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(95)00224-9</ArticleId><ArticleId IdType="pubmed">8566117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>